Subject(s)
Centers for Disease Control and Prevention, U.S./economics , National Institutes of Health (U.S.)/economics , Politics , United States Food and Drug Administration/economics , COVID-19/economics , COVID-19/prevention & control , Centers for Disease Control and Prevention, U.S./organization & administration , Humans , National Institutes of Health (U.S.)/organization & administration , United States , United States Food and Drug Administration/organization & administrationSubject(s)
COVID-19/epidemiology , COVID-19/virology , Disaster Planning/methods , Epidemiological Monitoring , Politics , SARS-CoV-2/genetics , Whistleblowing , Centers for Disease Control and Prevention, U.S./organization & administration , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/virology , Data Analysis , Disaster Planning/economics , Financing, Organized/economics , Genome, Viral/genetics , Genomics/economics , Genomics/trends , Humans , Leadership , Pandemics , SARS-CoV-2/isolation & purification , Sequence Analysis , United States/epidemiologyABSTRACT
OBJECTIVES: Federal open-data initiatives that promote increased sharing of federally collected data are important for transparency, data quality, trust, and relationships with the public and state, tribal, local, and territorial partners. These initiatives advance understanding of health conditions and diseases by providing data to researchers, scientists, and policymakers for analysis, collaboration, and use outside the Centers for Disease Control and Prevention (CDC), particularly for emerging conditions such as COVID-19, for which data needs are constantly evolving. Since the beginning of the pandemic, CDC has collected person-level, de-identified data from jurisdictions and currently has more than 8 million records. We describe how CDC designed and produces 2 de-identified public datasets from these collected data. METHODS: We included data elements based on usefulness, public request, and privacy implications; we suppressed some field values to reduce the risk of re-identification and exposure of confidential information. We created datasets and verified them for privacy and confidentiality by using data management platform analytic tools and R scripts. RESULTS: Unrestricted data are available to the public through Data.CDC.gov, and restricted data, with additional fields, are available with a data-use agreement through a private repository on GitHub.com. PRACTICE IMPLICATIONS: Enriched understanding of the available public data, the methods used to create these data, and the algorithms used to protect the privacy of de-identified people allow for improved data use. Automating data-generation procedures improves the volume and timeliness of sharing data.
Subject(s)
COVID-19/epidemiology , Centers for Disease Control and Prevention, U.S./organization & administration , Confidentiality/standards , Data Anonymization/standards , Centers for Disease Control and Prevention, U.S./standards , Humans , Pandemics , SARS-CoV-2 , United States/epidemiologySubject(s)
COVID-19/epidemiology , COVID-19/transmission , Centers for Disease Control and Prevention, U.S./history , Centers for Disease Control and Prevention, U.S./standards , Disease Transmission, Infectious , Politics , Aerosols , COVID-19/prevention & control , Centers for Disease Control and Prevention, U.S./organization & administration , Disease Transmission, Infectious/prevention & control , Disease Transmission, Infectious/statistics & numerical data , History, 20th Century , History, 21st Century , Humans , United States/epidemiologySubject(s)
Anti-HIV Agents/supply & distribution , COVID-19/epidemiology , HIV Infections/drug therapy , HIV Infections/epidemiology , Pandemics , Angola/epidemiology , Anti-HIV Agents/therapeutic use , Centers for Disease Control and Prevention, U.S./organization & administration , HIV-1/drug effects , Humans , Namibia/epidemiology , SARS-CoV-2/pathogenicity , Travel/statistics & numerical data , United StatesSubject(s)
Coronavirus Infections/prevention & control , Federal Government , Health Policy/trends , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Research Personnel , Advisory Committees/organization & administration , COVID-19 , Centers for Disease Control and Prevention, U.S./organization & administration , Coronavirus Infections/epidemiology , Humans , Masks , Minority Groups/statistics & numerical data , Pneumonia, Viral/epidemiology , Public Health Surveillance , Research Personnel/psychology , United States/epidemiologySubject(s)
Democracy , Federal Government , Leadership , Periodicals as Topic , Science , COVID-19 , COVID-19 Vaccines , Centers for Disease Control and Prevention, U.S./organization & administration , Centers for Disease Control and Prevention, U.S./standards , Contact Tracing , Coronavirus Infections/diagnosis , Coronavirus Infections/drug therapy , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Global Warming/prevention & control , Humans , Pandemics/prevention & control , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/transmission , Science/legislation & jurisprudence , Science/standards , Trust , United States/epidemiology , United States Environmental Protection Agency/organization & administration , Viral Vaccines , COVID-19 Drug TreatmentSubject(s)
Centers for Disease Control and Prevention, U.S./organization & administration , Coronavirus Infections/epidemiology , Data Collection , Federal Government , Information Dissemination , Pneumonia, Viral/epidemiology , COVID-19 , Centers for Disease Control and Prevention, U.S./standards , Hospital Administration/methods , Hospitals , Humans , Pandemics , Politics , Public Health/methods , United StatesABSTRACT
BACKGROUND: Coronavirus disease 2019 (COVID-19) has significantly impacted the health of millions of people around the world. The shortage of personal protective equipment, including N95 respirators, in hospital facilities has put frontline healthcare professionals at high risk for contracting this virus. AIM: To develop a reproducible and safe N95 respirator reprocessing method that satisfies all presented regulatory standards and that can be directly implemented by hospitals using existing available equipment. METHODS: A non-toxic gravity steam reprocessing method has been developed for the reuse of N95 respirators consisting of 30 min of steam treatment at 121°C followed by 30 min of heat drying. Samples of model number 1860, 1860s, 1870+, and 9105 N95 respirators were either collected from hospitals (for microbiology testing) or purchased new (for functionality testing), with all functionality tests (i.e. filter efficiency, fit evaluation, and strap integrity) performed at the Centers for Disease Control and Prevention using standard procedures established by the National Institute for Occupational Safety and Health. FINDINGS: All tested models passed the minimum filter efficiency of 95% after three cycles of gravity steam reprocessing. The 1870+ N95 respirator model is the most promising model for reprocessing based on its efficient bacterial inactivation coupled with the maintenance of all other key functional respirator properties after multiple reprocessing steps. CONCLUSIONS: The gravity steam method can effectively reprocess N95 respirators over at least three reprocessing cycles without negatively impacting the functionality requirements set out by regulators. Enabling the reuse of N95 respirators is a crucial tool for managing both the current pandemic and future healthcare crises.
Subject(s)
COVID-19/transmission , Equipment Reuse/standards , N95 Respirators/supply & distribution , Steam/adverse effects , Sterilization/instrumentation , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/virology , Centers for Disease Control and Prevention, U.S./organization & administration , Decontamination/methods , Disease Transmission, Infectious/prevention & control , Health Facilities/standards , Health Facilities/statistics & numerical data , Humans , N95 Respirators/standards , National Institute for Occupational Safety and Health, U.S./organization & administration , Personal Protective Equipment/supply & distribution , Respiratory Protective Devices/standards , Respiratory Protective Devices/virology , SARS-CoV-2/genetics , United StatesABSTRACT
Coronavirus disease 2019 (COVID-19) is a viral respiratory illness caused by SARS-CoV-2. During January 21-July 25, 2020, in response to official requests for assistance with COVID-19 emergency public health response activities, CDC deployed 208 teams to assist 55 state, tribal, local, and territorial health departments. CDC deployment data were analyzed to summarize activities by deployed CDC teams in assisting state, tribal, local, and territorial health departments to identify and implement measures to contain SARS-CoV-2 transmission (1). Deployed teams assisted with the investigation of transmission in high-risk congregate settings, such as long-term care facilities (53 deployments; 26% of total), food processing facilities (24; 12%), correctional facilities (12; 6%), and settings that provide services to persons experiencing homelessness (10; 5%). Among the 208 deployed teams, 178 (85%) provided assistance to state health departments, 12 (6%) to tribal health departments, 10 (5%) to local health departments, and eight (4%) to territorial health departments. CDC collaborations with health departments have strengthened local capacity and provided outbreak response support. Collaborations focused attention on health equity issues among disproportionately affected populations (e.g., racial and ethnic minority populations, essential frontline workers, and persons experiencing homelessness) and through a place-based focus (e.g., persons living in rural or frontier areas). These collaborations also facilitated enhanced characterization of COVID-19 epidemiology, directly contributing to CDC data-informed guidance, including guidance for serial testing as a containment strategy in high-risk congregate settings, targeted interventions and prevention efforts among workers at food processing facilities, and social distancing.